Axol Bioscience

About Axol Bioscience

Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in high-performance iPSC-derived cells and industry-leading laboratory services. With over a decade of expertise, they partner with global pharmaceutical companies, CROs, biotech firms, startups, and academic institutions to advance iPSC-based models in drug discovery and disease research. Their mission is to close the translational gap by developing physiologically relevant in vitro systems for improved consistency in human disease modeling and compound testing.

Products & Services

axoCells™:A range of iPSC-derived cells including Cortical Excitatory Neurons, Striatal Neurons, Microglia, Astrocytes, Motor Neurons, Sensory Neurons, Retinal Pigment Epithelium Cells (RPE), Sebocytes, Melanocytes, Ventricular Cardiomyocytes, Atrial Cardiomyocytes, and related media like MyoMax Maturation Media.

axoServices™:Custom lab services including iPSC banking, reprogramming, differentiation, gene editing, functional QC, cellular assays, multi-electrode array (MEA), assay development for microphysiological systems (MPS), and CRO supply and support.

Disease Lines Library:A commercial library of 70 iPSCs from patient and healthy donors for disease modeling.

Custom Manufacturing:Custom production of iPSC-derived cells using Axol’s library, client’s library, or third-party sources, supporting small runs to long-term supply agreements.

Compound Screening and Disease Modeling:iPSC-derived models for neuroscience, neuroinflammation, pain & sensation, cardiotoxicity, Dry-AMD, and dermatology research.

Specialties

Human Induced Pluripotent Stem Cell (iPSC) Technologies iPSC-Derived Cell Manufacturing Disease Modeling Drug Discovery Neuroscience (ALS, Alzheimer's, Huntington's, Parkinson's, Neuroinflammation) Cardiovascular Research Ophthalmology (Dry-AMD) Pain & Sensation Research Dermatology Custom Lab Services (Reprogramming, Gene Editing, Assay Development)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Unknown T: - FT: Unknown	A: 2800000 MR: - FA: $2.8M FAN: 2800000	D: 2026-01-13 FD: 2026-01-13	2 investors

Unknown Latest

2026-01-13

$2.8M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan Milner

Founder and Former CEO

L

Liam Taylor

Chief Executive Officer

A

Ashley Barnes

Expert in Drug Discovery and iPSC Technologies

S

Sonya Ansell

Head of Human Resources

M

Mhairi Rodgers

Head of Operations

O

Oliver Richardson

ACA Chartered Accountant

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Axol Bioscience Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised